UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE (I-MAK), INC. Petitioner

v.

GILEAD PHARMASSET LLC Patent Owner

Case No. IPR2018-00120 U.S. Patent No. 7,964,580

PETITION FOR INTER PARTES REVIEW



TABLE OF CONTENTS

| I. | INTR | TRODUCTION | | | | |
|-------|---------------------------------|--|---|--|--|--|
| II. | MANDATORY NOTICES | | | | | |
| | A. | Real Parties-in-Interest (37 C.F.R. § 42.8(b)(1)) | 2 | | | |
| | B. | Related Matters (37 C.F.R. § 42.8(b)(2)) | 2 | | | |
| | C. | Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)) | 2 | | | |
| | D. | Service Information (37 C.F.R. § 42.8(b)(4)) | 2 | | | |
| III. | REQUIREMENTS FOR REVIEW | | | | | |
| | A. | Grounds For Standing | 3 | | | |
| | B. | Identification of Challenge | 3 | | | |
| IV. | OVE | TERVIEW OF THE '580 PATENT4 | | | | |
| V. | FILE | LE HISTORY OF THE '580 PATENT5 | | | | |
| VI. | PERS | PERSON OF ORDINARY SKILL IN THE ART5 | | | | |
| VII. | CLAIM CONSTRUCTION | | | | | |
| VIII. | BACKGROUND KNOWLEDGE IN THE ART | | | | | |
| | A. | The Use of Nucleoside Analogs As Antiviral Agents And Their Mechanism of Action Were Known | 7 | | | |
| | В. | Anti-Viral Nucleosides Must Be Converted Into Their Triphosphates To Be Active, Monophosphorylation Was The Rate-Limiting Step In Such Conversion, and 5'-Phosphate Prodrugs Enabled Nucleosides To Overcome This Limitation | | | | |
| | C. | The Means Were Available to Determine Which Nucleosides Were Kinase Dependent | 8 | | | |



| | D. | | rowing The Selection Of Options For The Phosphoramidate drug | 19 | | |
|-----|-----|--|--|----|--|--|
| | E. | Phosphoramidates Improved Nucleosides | | | | |
| | F. | The '580 Patent Acknowledges This Common Knowledge | | | | |
| IX. | SCC | PE A | ND CONTENT OF THE PRIOR ART | 22 | | |
| | A. | Clar | k '147 | 22 | | |
| | B. | Clark 2005 | | | | |
| | C. | Perrone | | | | |
| | D. | McC | Guigan '327 | 26 | | |
| X. | CLA | LAIMS 1-14 ARE UNPATENTABLE27 | | | | |
| | A. | Grounds1: Claims 1-14 Were Obvious Over Clark '147, Clark 2005 and Perrone | | | | |
| | | 1. | Claims 1 and 8 (compound) | 28 | | |
| | | 2. | Claims 2, 3, 9 and 10 (compositions comprising compound) | 42 | | |
| | | 3. | Claims 4, 5, 11 and 12 (methods of treating viral infections) | 43 | | |
| | | 4. | Claims 6, 7, 13 and 14 (process of preparing and product) | 44 | | |
| | B. | | unds 2: Claims 1-14 Were Obvious Over Clark '147, Clark 20 McGuigan '327 | | | |
| | | 1. | Claims 1 and 8 (compound) | 45 | | |
| | | 2. | Claims 2, 3, 9 and 10 (compositions comprising compound) | 57 | | |
| | | 3. | Claims 4, 5, 11 and 12 (methods of treating viral infections) | 57 | | |
| | | 4. | Claims 6, 7, 13 and 14 (process of preparing and product) | 58 | | |
| ΧI | CON | JCLU! | SION | 61 | | |



| XII. | APPENDIX – LIST OF EXHIBITS | 63 |
|-------|-----------------------------|----|
| XIII. | CERTIFICATE OF COMPLIANCE | 64 |
| XIV | CERTIFICATE OF SERVICE | 65 |



I. INTRODUCTION

Initiative for Medicines, Access & Knowledge (I-MAK), Inc. ("Petitioner") requests *inter partes* review ("IPR") of all 14 claims of United States Patent No. 7,964,580 to Sofia et al. ("the '580 patent"; EX1001) under the provisions of 35 U.S.C. § 311, § 6 of the Leahy-Smith America Invents Act ("AIA"), and 37 C.F.R. § 42.100 et seq. The '580 patent issued on June 21, 201, and is currently assigned to Gilead Pharmasset LLC ("Patent Owner"). This petition demonstrates that all 14 claims of the '580 patent are unpatentable.

The '580 patent claims pharmaceutical compounds, compositions and methods that were obvious in light of the prior art. Specifically, the '580 claims a specific prodrug form of a specific nucleoside compound, but the prodrug technique used was by Patent Owner was entirely conventional and the nucleoside compound to which Patent Owner applied the prodrug technique had been previously disclosed (and patented) by Patent Owner years before. Taking a known prodrug approach and applying it to a known nucleoside is not an invention. It's obvious.

Thus, the '580 patent's claims are unpatentable and should be cancelled.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

